Abiopharma

New Form 424B2 - BARCLAYS BANK PLC <b>Filed:</b> 2026-08-28 <b>AccNo:</b> 0000950103-26-013051 <b>Size:</b> 964 KB

FRO – Q2 2026 Presentation

General Announcement: Net Asset Value Per Unit

New Form N-PX - BLACKROCK CORPORATE HIGH YIELD FUND, INC. <b>Filed:</b> 2026-08-28 <b>AccNo:</b> 0001438934-26-002379 <b>Size:</b> 62 KB

New Form S-8 - Jumia Technologies AG <b>Filed:</b> 2026-08-28 <b>AccNo:</b> 0001213900-26-094784 <b>Size:</b> 519 KB

New Form 424B2 - BARCLAYS BANK PLC <b>Filed:</b> 2026-08-28 <b>AccNo:</b> 0000950103-26-013050 <b>Size:</b> 350 KB

Broader Defense Platform Takes Shape as NAPC Defense Builds Momentum Under New NAPD Identity

Glucose Health, Inc. (OTCID: GLUC) Appoints Consumer Products Industry Veteran John Duffy as Chief Executive Officer to Accelerate Growth, Elevate Brand Leadership, and Maximize Long-Term Shareholder Value

New Form 424B2 - UBS AG <b>Filed:</b> 2026-08-28 <b>AccNo:</b> 0001839882-26-042124 <b>Size:</b> 1 MB

New Form N-PX - BLACKROCK DEBT STRATEGIES FUND, INC. <b>Filed:</b> 2026-08-28 <b>AccNo:</b> 0001438934-26-002374 <b>Size:</b> 19 KB

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Changes in Interest of Director - Chong Juin Kuan

(10% Negative) BIOATLA, INC. (BCAB) Announces Clinical Trial Timeline Adjustment

New Form 424B2 - GOLDMAN SACHS GROUP INC <b>Filed:</b> 2026-08-28 <b>AccNo:</b> 0001193125-26-372882 <b>Size:</b> 994 KB

(95% Positive) SCIENCE APPLICATIONS INTERNATIONAL CORP (SAIC) Reports Q3 2026 Financial Results

New Form 424B2 - JPMORGAN CHASE & CO <b>Filed:</b> 2026-08-28 <b>AccNo:</b> 0001918704-26-025277 <b>Size:</b> 1 MB